Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 23;7:97. doi: 10.1038/s41698-023-00453-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Newly acquired chromosome arm aneuploidy during the relapse of lower grade astrocytoma (outer-most circle, n = 11), grade 4 astrocytoma (middle circle, n = 8) and GB (inner-most circle, n = 46). Copy number variations of 39 chromosome arms were showed. Red color represents gain and blue represents loss. Patients in this analysis were all from this study. Overall survival for lower grade astrocytoma and GB patients with or without newly acquired 1q gain (b) and 6p gain (c) at recurrence. P values were obtained from the log-rank test. Survival analysis was performed with the combination of our data (n = 49) and public data downloaded from cBioPortal (n = 187). Cases without arm gain (loss) in both primary and recurrent tumors were classified into “None” group. Cases with arm gain (loss) in recurrent tumor and without gain (loss) in primary tumor were classified into “Gain (Loss)” group. d CNVs in arm levels (1q, 6p and 13q) and gene levels (RB1, VEGFA) in primary and recurrent tumors for 65 patients. Histological grade and WHO CNS5 grade were shown.